• Blog
  • Constipation Treatment Market Forecast Analysis | 2023-2028

    Constipation Treatment Market Forecast Analysis | 2023-2028

    Constipation Treatment Market Forecast Analysis | 2023-2028
    Report code - SR1703 Delivery - 2 Weeks
    Constipation Treatment Market Size, Share, Trend, Forecast, & Industry Analysis: 2023- See more...

    Market Insights

    The constipation treatment market is estimated to grow from USD 18.82 billion in 2022 and is likely to grow at a CAGR of 7.60% during 2023-2028 to reach USD 29.29 billion by 2028.

    Constipation Treatment Market Snapshot

    Wish to get a Free Sample? Register Here.

    What is Constipation Treatment?

    Constipation is referred to as a chronic disorder, which results in indifferent bowel movements and primarily leads to hardened feces, which persists for several weeks and in some cases even longer. It causes infrequent stools and difficult stool passage with stiffness and pain. Acute constipation can result in blocking of the intestine which can require surgical intervention.

    The symptoms of constipation include lower abdominal discomfort, bloating, anal fissures caused by hard stools, rectal bleeding, gastric pain, incomplete evacuation, and strain during bowel movement. This primarily happens when the colon has absorbed excessive water from the food which is present in the colon.

    Constipation Treatment Market Reports Overview

    Market Size in 2028

    USD 29.29 Billion

    Market Size in 2022

    USD 18.82 Billion

    Market Growth (2023-2028)

    CAGR of 7.60%

    Base Year of Study

    2022

    Trend Period

    2017-2021

    Forecast Period

    2023-2028

    Market Drivers

    The constipation treatment market is driven by a host of factors, some of which are noted below:

    The rise in the geriatric population, increasing expenditure in R&D activities for the development of innovative drugs & sedentary lifestyle. 

    Developments in healthcare infrastructure, changing dietary habits, and insufficient consumption of fast food in high quantity.

    Moreover, increasing complexity in the healthcare industry to offer better treatment & solutions to the upcoming challenges.

    Also, the presence of qualified healthcare professionals coupled with the high prevalence of IBS & chronic constipation offers immense growth opportunities to the industry players in the coming years.

    Segment Analysis

    Disease Trends

    The market has been classified into chronic idiopathic constipation (CIC), irritable bowel syndrome with constipation (IBS-C) & opioid-induced constipation (OIC). Under these, chronic idiopathic constipation (CIC) held the largest share of the market in 2022 & & is expected to remain the largest market for constipation treatment during the forecast period. The growing prevalence of CIC around the world, which is driven by factors such as sedentary lifestyles, bad eating habits, and an aging population, provides a larger patient pool in need of therapy. Furthermore, advances in diagnostic procedures and increased awareness of CIC have resulted in improved case identification and reporting, driving the demand for treatment options even higher.

    Therapeutic Trends

    The market has been divided into laxatives, chloride channel activators, peripherally acting Mu-opioid receptor antagonists, GC-C agonists, and others. The laxatives segment held a significant market share in 2022 & is estimated to remain dominant during the forecast period. Laxatives are widely used to treat constipation. They're often used if lifestyle changes, such as drinking plenty of fluid, increasing the amount of fiber in your diet, and taking regular exercise, have not helped reduce constipation, thus augmenting the market growth.

    Regional Trends

    North America accounted for the highest share of the market in 2022 and is expected to grow at a significant CAGR during the review period. The market growth can be ascribed to the growing prevalence of chronic constipation, growing investment in healthcare, presence of a large number of product manufacturers, well-established healthcare facilities, increasing sedentary lifestyle, and presence of a huge patient population base in the region.

    The Asia-Pacific is expected to grow at the highest CAGR during the review on account of the growth of the major end-use industries. This growth is mainly ascribed to the rising prevalence of bowel and gastric diseases, growth in healthcare expenditure, surging demand for diagnostic tests, rise in disposable income, strong focus on early diagnosis & treatment of GI diseases, and strong proliferation of healthcare infrastructure.

    constipation treatment market By Region

    Want to know which region offers the best growth opportunities? Register Here.

    Segmentation

    This report studies the market covering a period of 12 years of trend and forecast. The report provides detailed insights into the market dynamics to enable informed business decision-making and growth strategy formulation based on the opportunities present in the market.

    The constipation treatment market is segmented into the following categories:

    By Disease Type

    • Chronic idiopathic constipation (CIC)
    • Irritable bowel syndrome with constipation (IBS-C)
    • Opioid-induced constipation (OIC)

    By Therapeutic Type

    • Laxatives
    • Chloride Channel Activators
    • Peripherally Acting Mu-Opioid Receptor Antagonists
    • GC-C Agonists
    • Others

    By Region

    • North America (Country Analysis: The USA, Canada, and Mexico),
    • Europe (Country Analysis: Germany, France, The UK, Russia, and the Rest of Europe),
    • Asia-Pacific (Country Analysis: China, India, Australia, South Korea, and the Rest of Asia-Pacific),
    • Rest of the World (Country Analysis: Saudi Arabia, Brazil, and Others).

    Key Players

    The following are some of the key players operating in the constipation treatment market-

    • Takeda Pharmaceutical Company Ltd. (Japan)
    • Ironwood Pharmaceuticals, Inc. (US)
    • Salix Pharmaceuticals, Inc. (US)
    • Abbott Laboratories
    • AstraZeneca Plc (UK)
    • Cosmo Pharmaceuticals NV (Ireland)
    • Sanofi S.A. (France)
    • AbbVie's Inc
    • Bayer AG (Germany)
    • Bausch Health Companies Inc. (Canada)

    Report Features

    This report provides market intelligence in the most comprehensive way. The report structure has been kept such that it offers maximum business value. It provides critical insights into the market dynamics and will enable strategic decision-making for the existing market players as well as those willing to enter the market.

    What Deliverables Will You Get in this Report?

    Key questions this report answers

    Relevant contents in the report

    How big is the sales opportunity?

    In-depth Analysis of the constipation treatment market

    How lucrative is the future?

    The market forecast and trend data and emerging trends

    Which regions offer the best sales opportunities?

    Global, regional, and country-level historical data and forecasts

    Which are the most attractive market segments?

    Market segment analysis and Forecast

    Which are the top players and their market positioning?

    Competitive landscape analysis, Market share analysis

    How complex is the business environment?

    Porter’s five forces analysis, PEST analysis, Life cycle analysis

    What are the factors affecting the market?

    Drivers & challenges

    Will I get the information on my specific requirement?

    10% free customization

    Target Audience

    The target audience of the constipation treatment market includes-

    • Vendors
    • Manufacturers
    • Distributors
    • Organizations
    • Government Bodies.

    Covid-19 Impact Analysis

    The outbreak of COVID-19 moderately impacted the constipation treatment industry as the pandemic adversely affected international trade activities and supply chains across the globe. The pandemic resulted in a diversion of the medical field towards treating COVID-19, thus the funding for R&D activities pertaining to constipation treatment has been reduced, thereby affecting the market growth amid the pandemic.

    Research Methodology

    This report offers high-quality insights and is the outcome of a detailed research methodology comprising extensive secondary research, rigorous primary interviews with industry stakeholders, and validation and triangulation with Stratview Research’s internal database and statistical tools.

    More than 1,000 authenticated secondary sources, such as company annual reports, fact books, press releases, journals, investor presentations, white papers, patents, and articles have been leveraged to gather the data.

    We conducted more than 10 detailed primary interviews with the market players across the value chain in all four regions and with industry experts to obtain both qualitative and quantitative insights.

    Customization Option

    Stratview Research offers one of the following free customization options to our respectable clients:

    Company Profiling

    • Detailed profiling of additional market players (up to three players)
    • SWOT analysis of key players (up to three players)

    Competitive Benchmarking

    Benchmarking of key players on the following parameters: Product portfolio, geographical reach, regional presence, and strategic alliances

    Custom Research: Stratview Research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry to sales@stratviewresearch.com.

    Frequently Asked Questions (FAQs)

    Constipation is referred to as a chronic disorder, which results in indifferent bowel movements and primarily leads to hardened feces, which persists for several weeks and in some cases even longer. It causes infrequent stools and difficult stool passage with stiffness and pain. Acute constipation can result in blocking of the intestine which can require surgical intervention.

    The market is estimated to grow from USD 18.82 billion in 2022 to USD 29.29 billion by 2028.

    The market is estimated to grow at a healthy CAGR of 7.60% during the forecast period.

    Takeda Pharmaceutical Company Ltd. (Japan), Ironwood Pharmaceuticals, Inc. (US), Salix Pharmaceuticals, Inc. (US), Abbott Laboratories, AstraZeneca Plc (UK), Cosmo Pharmaceuticals NV (Ireland), Sanofi S.A. (France), AbbVie's Inc, Bayer AG (Germany), Bausch Health Companies Inc. (Canada) are among the key players in the market.

    North America accounted for the highest share of the market in 2022 and is expected to grow at a significant CAGR during the review period.

    Asia-pacific is expected to grow at the highest CAGR in the market in the next five years.

    The rise in the geriatric population, increasing expenditure in R&D activities for the development of innovative drugs & sedentary lifestyles & developments in healthcare infrastructure, changing dietary habits, and insufficient consumption of fast food in high quantity are some of the factors driving the market's growth during the forecast period.